
Conference Coverage
Latest News

Novel mechanisms reshaping the phase 3 pipeline in wet and dry AMD

Recent increasing awareness and interest in Demodex blepharitis readily apparent: half-year recap

Neovascular MacTel: Mark Barakat, MD, on catching conversion and when to refer

Eyes on July 2026: Approvals, pipeline momentum, and AI take center stage

Bringing the Gulani classification to life: 4 pathways to the same destination

Shorts










Digital Edition








Podcasts
Continuing Medical Education
All News

The annual Best Hospitals report from US News & World Report compares more than 4500 hospitals across 14 specialties and 22 procedures and conditions.

The first half of 2026 turned on inherited pediatric eye disease, with 2 gene therapy programs advancing toward registration and a high-profile complete response letter in a childhood-onset optic neuropathy.

The FDA has cleared an IND for RAG-1C, a first-in-class saRNA therapy targeting proliferative vitreoretinopathy.

Home OCT now gives us the next dimension: time.

Retina specialists Baruch D. Kuppermann, MD, PhD, and Firas M. Rahhal, MD, discuss the significance of bevacizumab-vikg's approval for wet AMD and its impact on physicians and patients.

Seven-year Vestrum data: anti-VEGF gaps hit 40% of patients with wet AMD by year 1, worsening vision.

An investigational drug has shown positive activity against metastatic uveal melanoma in a phase 1 study.

In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and technology are making the procedure more precise for younger patients.

Findings highlight the need for routine bilateral endothelial assessment in herpetic eye disease

When patients fall outside pivotal clinical trial criteria, retina specialists factor in real-world judgment to guide treatment.

Steffen Schmitz-Valckenberg, MD, discusses how optical coherence tomography-based models may enable rapid, noninvasive assessment of functional loss in GA at Angiogenesis 2026.

Frantz EyeCare reports 98% of Light Adjustable Lens patients achieved refractive accuracy within ±0.50 D of target, exceeding published national cataract surgery benchmarks.

The phase 2 EVIAN study (Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis) (NCT 04522661) showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treament of prescribing antibiotics first.

Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.

Arun C. Gulani, MD, introduces the Gulani classification of refractive lens exchange, a 4-type framework for individualizing premium IOL selection and surgical strategy around each eye's visual potential rather than its diagnosis.


























